Arterial hypertension and cognitive function

Cover Page
  • Authors: Ostroumova O.D1,2, Dudaev V.A1, Galeeva N.Y.3
  • Affiliations:
    1. A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
    2. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
    3. City clinical hospital №70 of the Moscow health care department
  • Issue: Vol 17, No 1 (2015)
  • Pages: 6-10
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/94203
  • ID: 94203

Cite item

Full Text

Abstract

The article presents the definition, classification and pathogenetic mechanisms of cognitive impairment in patients with arterial hypertension (AH). Discusses the literature on the relationship of hypertension with risk of dementia. The possibilities of antihypertensive therapy in the prevention of dementia. Discussed in detail the results of the study Syst-Eur (Systolic Hypertension in Europe), in which the calcium antagonist (CA) nitrendipine ± enalapril reduced the risk of developing dementia, including Alzheimer's disease, new cases, 50%. Neuroprotective action mechanisms are considered as a whole and AK nitrendipine in particular.

About the authors

O. D Ostroumova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: ostroumova.olga@mail.ru
д-р мед. наук, проф. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова; проф. каф. клинической фармакологии и профболезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

V. A Dudaev

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

N. Yu Galeeva

City clinical hospital №70 of the Moscow health care department

- врач приемного отд-ния ГБУЗ ГКБ №70 111399, Russian Federation, Moscow, Federativnyi prosp., d. 17

References

  1. Захаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009.
  2. Larrieu S. Letenneur L, Orgogozo J.M. Incidence and outcome of mild cognitive impairment in a population - based prospective cohort. Neurology 2002; 59: 1594-9.
  3. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2010.
  4. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-26.
  5. Henderson A.S. Dementia. World Health Organization, Geneva, 1994.
  6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
  7. Захаров В.В. Нарушение памяти в пожилом возрасте: современные возможности профилактики и терапии. Рус. мед. журн. 2012; 8: 422-6.
  8. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
  9. Launer L.J, Masaki K, Petrovitch H et al. The assoсiation between midlife blood pressure levels and late - life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-51.
  10. Cacciatore F, Abete P, Ferrara N et al. The role of blood pressure in cognitive impairment in an elderly population. J Hypertens 2002; 15: 135-42.
  11. Elias P.K, D'Agostino R.B, Elias M.F, Wolf P.A. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res 1995; 21: 393-417.
  12. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle - age in the Whitehall II study. J Clin Epidemiol 2005; 58: 1308-15.
  13. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension of the European Society of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.
  14. Borson S, Scanlan J, Brush M et al. The miniog: a cognitive 'vital signs' measure for dementia screening in multi - lingual elderly. Int J Geriatr Psychiatry 2000; 15: 1021-7.
  15. Захаров В.В. Нейропсихологические тесты. Необходимость и возможность применения. Consiliun Medicum. 2011; 2: 82-90.
  16. Marpillat N.L, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta - analysis. J Hypertens 2013; 31 (6): 1073-82.
  17. Staessen J.A, Fagard R, Thijs L et al. Randomised double - blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
  18. Forette F, Seux M-L, Staessen J.A et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046-52.
  19. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752-68.
  20. Mason R.P, Leeds P.R, Jacob P.F et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448-56.
  21. Zipfel G.J, Lee J.M, Choi D.W. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543-4.
  22. Thibault O, Porter N.M, Chen K.C. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417-33.
  23. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81-8.
  24. Hong Y.L. The relationship between calcium antagonist - induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589-97.
  25. Murzenok P.P, Huang B.S, Leenen F.H.H. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631-6.
  26. Gould R.J, Murphy K.M.M, Snyder S.H. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217-33.
  27. De la Sierra A, Roca-Cusachs A, Redón J et al. Effectiveness and tolerability of fixed - dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post - marketing, multicentre, prospective CENIT study. Clin Drug Investig 2009.
  28. Eber B, Weber T, Artmann A et al. Fixkombination Enalapril/Nitrendipin in der täglichen Praxis - Effektivität und Verträglichkeit bei 1.262 österreichischen Hypertonikern. Journal für Hypertonie 2007; 11 (2): 22-5.
  29. Trenkwalder P. The Efficacy and Tolerability of an Antihypertensive Fixed Combination of Enalapril and Nitrendipine. Perfusion 2004; 7: 394-9.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies